Article
A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1.
Journal of hepatology - 1 Jul 2013
Lawitz Eric, Poordad Fred, Kowdley Kris V, Cohen Daniel E, Podsadecki Thomas, Siggelkow Sara, Larsen Lois, Menon Rajeev, Koev Gennadiy, Tripathi Rakesh, Pilot-Matias Tami, Bernstein Barry
Abstract excerpt
BACKGROUND & AIMS: ABT-450 (combined with low-dose ritonavir, ABT-450/r) is a potent HCV NS3 protease inhibitor, and ABT-072 is a non-nucleoside NS5B polymerase inhibitor. The goal of this study was to evaluate the safety, tolerability, and efficacy of the peginterferon-free combination of ABT-450/r and ABT-072 with ribavirin in treatment-naïve patients with IL28B CC genotype, infected with HCV genotype 1....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.